All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @realalejandroreyes on TikTok · 40s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @realalejandroreyes's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00How would you feel taking tests of Morland?
  2. 0:02And what are the benefits?
  3. 0:02So pretty much, you're going to have better recovery,
  4. 0:05better sleep, when you take it at night,
  5. 0:07you're going to knock out like you gave.
  6. 0:09You're not a benefit of testing one.
  7. 0:10It's to help show up that little belly fat,
  8. 0:12that stubborn belly fat, that's extremely hard to lose.
  9. 0:15And it also helps decrease lipogenesis,
  10. 0:17which is the creation of fat cells.
  11. 0:19Increased liposis, which is a breakdown of fat cells,
  12. 0:21and it's going to help with producing
  13. 0:23what you're going to grow from the body.
  14. 0:25The reason why you're taking it to the bed
  15. 0:26is because you're producing what you're going to grow
  16. 0:28from the body, and you want those benefits
  17. 0:29when you're sleepy, so that you're producing more
  18. 0:32both more, and then the enemy has recovery,
  19. 0:34sleep, and it's going to help with fat muscles.
  20. 0:38But yeah, you have any questions?
  21. 0:39It's your media.

Peptide therapy TikTok advice: what the science actually supports

realalejandroreyes

TikTok creator

10.0K viewsWatch on TikTok

Quick answer

Tesamorelin is an FDA-approved GHRH analog with documented efficacy for reducing visceral adipose tissue in HIV-associated lipodystrophy, based on RCT data. Its use in metabolically healthy adults for general fat loss or recovery is off-label, and long-term safety data in that population remains limited. Clinically relevant risks include glucose dysregulation and IGF-1 elevation, which require baseline metabolic assessment before prescribing.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Peptide therapy TikTok advice: what the science actually supports, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Peptide therapy TikTok advice: what the science actually supports is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Peptide therapy TikTok advice: what the science actually supports" from realalejandroreyes. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tesamorelin is an FDA-approved GHRH analog with documented efficacy for reducing visceral adipose tissue in HIV-associated lipodystrophy, based on RCT data.

The reason this review is not generic is the source wording and the canonical claim label "peptides if you have questions i got you." In this clip, the useful excerpt is: "How would you feel taking tests of Morland?" That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against EGRIFTA (tesamorelin for injection) FDA Prescribing Information (2024), Egrifta (tesamorelin) Original NDA 022505 FDA Approval Letter (2010), and Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial (2010), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Falutz et al.
People who land here are usually trying to understand whether the Peptide social video fact-checks claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' Peptide social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Tesamorelin is an FDA-approved GHRH analog with documented efficacy for reducing visceral adipose tissue in HIV-associated lipodystrophy, based on RCT data.

FormBlends verdict

Peptide social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Tesamorelin is an FDA-approved GHRH analog with documented efficacy for reducing visceral adipose tissue in HIV-associated lipodystrophy, based on RCT data. Its use in metabolically healthy adults for general fat loss or recovery is off-label, and long-term safety data in that population remains limited. Clinically relevant risks include glucose dysregulation and IGF-1 elevation, which require baseline metabolic assessment before prescribing.
  • Tesamorelin is FDA-approved (as Egrifta) only for visceral fat reduction in HIV-associated lipodystrophy, not for general fat loss or body recomposition.
  • Falutz et al. (2010, Lancet HIV) found significant increases in HbA1c in some tesamorelin users, making glucose monitoring a clinical requirement, not optional.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Tesamorelin is FDA-approved (as Egrifta) only for visceral fat reduction in HIV-associated lipodystrophy, not for general fat loss or body recomposition.
  • Falutz et al. (2010, Lancet HIV) found significant increases in HbA1c in some tesamorelin users, making glucose monitoring a clinical requirement, not optional.
  • Nighttime dosing has a physiological rationale: GH secretion peaks during slow-wave sleep, and GHRH analogs amplify this pulse (Van Cauter et al., 2000, Sleep).
  • Compounded tesamorelin available through telehealth or peptide suppliers is not FDA-approved Egrifta. Purity and potency are not federally verified.
  • Tesamorelin raises IGF-1 levels, and chronically elevated IGF-1 is associated with increased cancer risk in observational data, a risk the video did not mention.
  • The visceral fat reduction in RCTs was documented in a specific patient population with lipodystrophy. Extrapolating those results to healthy adults is not scientifically supported.
  • Anyone considering tesamorelin needs a prescribing provider to assess fasting glucose, HbA1c, and metabolic baseline before starting, not a TikTok video.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @realalejandroreyes actually say?

The creator is talking about tesamorelin, a synthetic growth hormone-releasing hormone (GHRH) analog. The transcript is garbled in places, but the core claims are identifiable: tesamorelin improves recovery and sleep, burns "stubborn belly fat," decreases lipogenesis (fat cell creation), increases lipolysis (fat breakdown), and should be taken at night to align with the body's natural growth hormone pulse. These are real claims that deserve real scrutiny, not just a shrug.

To be fair, the creator is pointing toward mechanisms that actually exist in the literature. That's more than most peptide TikToks manage. But vague delivery and missing context can mislead people who are making actual health decisions based on a 60-second video.

Does the science back this up?

Partially, yes, and that's not nothing. Tesamorelin has one of the stronger evidence bases of any peptide in this category, which sets it apart from, say, BPC-157 or TB-500.

The FDA approved tesamorelin (brand name Egrifta) specifically for reducing visceral adipose tissue (VAT) in HIV-associated lipodystrophy. That approval is based on randomized controlled trials, including Stanley et al. (2012, NEJM) showing statistically significant reductions in visceral fat versus placebo. The mechanism the creator gestures at, increased lipolysis and reduced lipogenesis via elevated IGF-1 and growth hormone, is real and documented.

On sleep: growth hormone secretion is strongly tied to slow-wave sleep. A GHRH analog can amplify the nocturnal GH pulse, which is why nighttime dosing makes physiological sense. Van Cauter et al. (2000, Sleep) established this relationship clearly. The creator gets credit for the timing rationale, even if the explanation was muddled.

What did they get wrong (or right)?

The creator got the core mechanisms directionally correct but oversimplified in ways that matter.

  • Lipolysis and lipogenesis: Accurate that tesamorelin shifts the balance toward fat breakdown. But this effect is most documented for visceral fat specifically, not subcutaneous "belly fat" in general. Calling it "stubborn belly fat" glosses over that distinction in a way that sets up unrealistic expectations.
  • Sleep and recovery: The claim that "you're going to knock out" is anecdotal and unsupported by controlled data. Tesamorelin may enhance GH-related sleep quality effects, but it is not a sedative and the evidence for subjective sleep improvement in healthy adults is thin.
  • "Producing more both more": This is incoherent in the transcript, likely referring to IGF-1 or GH production. The idea is plausible but the delivery is not informative enough to evaluate fairly.
  • What they missed: No mention of the fact that tesamorelin is a prescription compound. No mention of side effects including fluid retention, joint pain, glucose dysregulation, and potential IGF-1-related risks with long-term use. That's a significant omission for a public-facing health video.

What should you actually know?

Tesamorelin is not a general-purpose fat loss peptide. Its FDA approval is narrow and specific. Using it outside that indication is off-label, and the long-term safety data in metabolically healthy adults is limited.

The nocturnal dosing logic is sound and grounded in endocrinology. If you are working with a physician who has prescribed tesamorelin, timing it with your natural GH pulse is reasonable. But "taking it to bed" is not a hack you pick up from TikTok.

Anyone considering tesamorelin should know: it can raise fasting glucose levels. Falutz et al. (2010, Lancet HIV) found meaningful increases in HbA1c in some participants. If you have prediabetes or insulin resistance, this is not a minor footnote. A prescribing provider needs to assess your metabolic baseline before this compound is appropriate.

Compounded tesamorelin, which is what most people outside HIV care are actually accessing, is not the same as FDA-approved Egrifta. Purity, potency, and sterility vary by compounding pharmacy. That difference is not academic.

Bottom line

This video is more grounded than the average peptide TikTok. The mechanism claims around lipolysis and nighttime GH pulses have real science behind them. But missing context about prescription status, side effects, glucose risk, and the specific population studied makes this a starting point at best, not medical guidance. The creator's confidence exceeds what the evidence supports for general use.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

realalejandroreyes · TikTok creator

10.0K views on this video

If you have questions I got you

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about tesamorelin?

Tesamorelin is FDA-approved (as Egrifta) only for visceral fat reduction in HIV-associated lipodystrophy, not for general fat loss or body recomposition.

What does the video say about falutz et al. (2010, lancet hiv) found significant increases in?

Falutz et al. (2010, Lancet HIV) found significant increases in HbA1c in some tesamorelin users, making glucose monitoring a clinical requirement, not optional.

What does the video say about nighttime dosing has a physiological rationale: gh secretion peaks during?

Nighttime dosing has a physiological rationale: GH secretion peaks during slow-wave sleep, and GHRH analogs amplify this pulse (Van Cauter et al., 2000, Sleep).

What does the video say about compounded tesamorelin available through telehealth?

Compounded tesamorelin available through telehealth or peptide suppliers is not FDA-approved Egrifta. Purity and potency are not federally verified.

What does the video say about tesamorelin raises igf-1 levels,?

Tesamorelin raises IGF-1 levels, and chronically elevated IGF-1 is associated with increased cancer risk in observational data, a risk the video did not mention.

What does the video say about the visceral fat reduction in rcts was documented in a?

The visceral fat reduction in RCTs was documented in a specific patient population with lipodystrophy. Extrapolating those results to healthy adults is not scientifically supported.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by realalejandroreyes, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.